A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer
Clinical Breast Cancer · 2024
DOI: 10.1016/j.clbc.2024.07.001 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Rushabh Kothari und 40 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Narayana Multispeciality Hospital, Opp. Rakhiyal Police Station, Ahmedabad, Gujarat, India. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Biosimilar Pharmaceuticals, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: To evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of ZRC-3277 (pertuzumab biosimilar) with Perjeta® (pertuzumab) in previously untreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). PATIENTS AND METHODS: This phase III, multicenter, double-blind study across 38 sites in India randomized (1:1) patients with HER2-positive MBC in either the ZRC-3277 or Perjeta® group. Both groups also received trastuzumab and docetaxel. Of 268 enrolled patients, mITT population had 243 patients (119 and 124 in the ZRC-3277 and Perjeta® groups, respectively). The primary objective was to compare the between-group objective response rate (ORR) after 6 cycles of treatment. ORR was determined by evaluating scans of computed tomography or magnetic resonance imaging following Response Evaluation Criteria in Solid Tumor (RECIST 1.1). Two-sided 95% confidence interval (95% CI) for the difference in ORR was determined to evaluate the noninferiority of ZRC-3277 to Perjeta®. The secondary outcomes included the assessment of PK, immunogenicity, and safety between the 2 groups. RESULTS: In the mITT population, 104 (87.39%) and 114 (91.94%) participants achieved the ORR in the ZRC-3277 and Perjeta® groups, respectively. For predefined -15% noninferiority margin, obtained 2-sided 95% CIs (-12.19%, 3.11%) for the difference in ORR (-4.55%) between the 2 groups demonstrated the noninferiority of ZRC-3277 to Perjeta®. PK, immunogenicity, and safety were not significantly different between the 2 groups. CONCLUSION: Efficacy, PK, immunogenicity, and safety profiles of ZRC-3277 was found to be similar to those of Perjeta®.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Department, Narayana Multispeciality Hospital, Opp. Rakhiyal Police Station, Ahmedabad, Gujarat, India.
- Clinical Research and Development Department, Zydus Research Center, Ahmedabad, India. Electronic address: maulik.doshi@zyduslife.com.
- Oncology Department, MNJ Institute of Oncology and Regional Cancer Centre, Hyderabad, Telangana, India.
- Oncology Department, HealthCare Global Enterprises Ltd #8, HCG Towers, Bengaluru, Karnataka, India.
- Oncoville Cancer Hospital and Research Centre, Oncology Department, Bengaluru, Karnataka, India.
- Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana, India.
Zitieren
APA
Kothari, R., Doshi, M., Chaithanya, P. K., Ct, S., Kumar, A., Mallavarapu, K. M., Nagarkar, R., Mahobia, V., Bhatt, N., Priyadarshini, K. L., Gogia, A., Maksud, T., Prasad, S., Velavan, K., L K, R., Ss, P., Talreja, V., Kalra, K., Nemade, B., …, & Parmar, D. (2024). A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.07.001
Vancouver
Kothari R, Doshi M, Chaithanya PK, Ct S, Kumar A, Mallavarapu KM, et al. A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.07.001
BibTeX
@article{Kothari2024,
author = {Kothari, Rushabh and Doshi, Maulik and Chaithanya, P K and Ct, Satheesh and Kumar, Anil and Mallavarapu, Krishna Mohan and Nagarkar, Rajnish and Mahobia, Vijay and Bhatt, Niraj and Priyadarshini, K L and Gogia, Ajay and Maksud, Tanveer and Prasad, Saurabh and Velavan, K and L K, Rajeev and Ss, Prakash and Talreja, Vikas and Kalra, Kaushal and Nemade, Bhushan and Dastidar, Aloke Ghosh and Gupta, Tarachand and Patil, Tushar and Bondarde, Shailesh and Patel, Pinakin and Gupta, Sudeep and Biswas, Ghanashyam and Vaghela, Manan and Mahato, Pinaki and Parekh, Honey and Kalloli, Mahesh and Shetty, Rachan and Prakash, Gaurav and Goel, Anil and Mandal, Srikrishna and Choudhury, Tamohan and Jain, Minish and Goswami, Chanchal and H M, Yathish Kumar and Mukherjee, K K and Shrivastava, Rahul and Parmar, Deven},
title = {A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer},
journal = {Clinical Breast Cancer},
year = {2024},
doi = {10.1016/j.clbc.2024.07.001}
}
EUVIMED